Comparison of Clinical and Biologic Significance of WT1 Mutations in Populations of Older (≥60 years[y]) and Younger (<60 y) Adult Patients (Pts) with Cytogenetically Normal (CN) De Novo Acute Myeloid Leukemia (AML): a Cancer and Leukemia Group B (CALGB) Study.
Heiko Becker(University of Freiburg), Clara D. Bloomfield(North Shore University Hospital), Kati Maharry(Peter MacCallum Cancer Centre), Michael D. Radmacher, Michael A. Caligiuri(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Maria R. Baer(University of Maryland, Baltimore), Guido Marcucci(City of Hope), Jonathan E. Kolitz(Memorial Sloan Kettering Cancer Center), Richard A. Larson(Urbana University), Andrew J. Carroll(University of Alabama at Birmingham), Krzysztof Mrózek(The Ohio State University), Peter Paschka(European Bioinformatics Institute), Dean Margeson(University of Iowa), Susan P. Whitman(The Ohio State University Wexner Medical Center), Sebastian Schwind, Yue-Zhong Wu(University of Iowa), Christian Langer(University Hospital Ulm)
Cited by 25
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
|Blood|2009|4.4k
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k